Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Salbutamol 100microg/dose / Ipratropium 20microg/dose inh
0301040R0AAAAAA
|
Salbutamol/ipratropium bromide | Salbutamol | Respiratory System | No data available |
|
Salbutamol 100micrograms/dose breath actuated inhaler
0301011R0AAADAD
|
Salbutamol | Salbutamol | Respiratory System | No data available |
|
Salbutamol 200 Cyclocaps
0301011R0BPACAV
|
Salbutamol Cyclocap | Salbutamol | Respiratory System | No data available |
|
Salbutamol 200microg/Beclometasone 100microg pdr caps
0302000C0AABLBL
|
Beclometasone dipropionate (Inhalation) | Beclometasone dipropionate | Respiratory System | No data available |
|
Salbutamol 200microgram inhalation pdr blist with device
0301011R0AAAIAI
|
Salbutamol | Salbutamol | Respiratory System | No data available |
|
Salbutamol 200microgram inhalation powder blisters
0301011R0AAAKAK
|
Salbutamol | Salbutamol | Respiratory System | No data available |
|
Salbutamol 200microgram inhalation powder capsules
0301011R0AAAVAV
|
Salbutamol | Salbutamol | Respiratory System | No data available |
|
Salbutamol 400 Cyclocaps
0301011R0BPADAW
|
Salbutamol Cyclocap | Salbutamol | Respiratory System | No data available |
|
Salbutamol 400microg/Beclometasone 200microg pdr caps
0302000C0AAAPAP
|
Beclometasone dipropionate (Inhalation) | Beclometasone dipropionate | Respiratory System | No data available |
|
Salbutamol 400microgram inhalation pdr blist with device
0301011R0AAAJAJ
|
Salbutamol | Salbutamol | Respiratory System | No data available |
|
Salbutamol 400microgram inhalation powder blisters
0301011R0AAALAL
|
Salbutamol | Salbutamol | Respiratory System | No data available |
|
Salbutamol 400microgram inhalation powder capsules
0301011R0AAAWAW
|
Salbutamol | Salbutamol | Respiratory System | No data available |
|
Salbutamol 4mg modified-release capsules
0301011R0AABMBM
|
Salbutamol | Salbutamol | Respiratory System | No data available |
|
Salbutamol 4mg modified-release tablets
0301011R0AABEBE
|
Salbutamol | Salbutamol | Respiratory System | No data available |
|
Salbutamol 5mg/50ml solution for infusion vials
0301011R0AABVBV
|
Salbutamol | Salbutamol | Respiratory System | No data available |
|
Salbutamol 8mg modified-release capsules
0301011R0AABPBP
|
Salbutamol | Salbutamol | Respiratory System | No data available |
|
Salbutamol 8mg modified-release tablets
0301011R0AABFBF
|
Salbutamol | Salbutamol | Respiratory System | No data available |
|
Salbutamol 95micrograms/dose dry powder inhaler
0301011R0AAAFAF
|
Salbutamol | Salbutamol | Respiratory System | No data available |
|
Salipraneb 0.5mg/2.5mg nebuliser soln 2.5ml amp (Actavis)
0301040R0BEAAAC
|
Salipraneb (Actavis) | Salbutamol | Respiratory System | No data available |
|
Salipraneb 0.5mg/2.5mg nebuliser soln 2.5ml ampoules (Arrow)
0301040R0BDAAAC
|
Salipraneb (Arrow) | Salbutamol | Respiratory System | No data available |
|
Salmeterol 50microgram inhalation pdr blist with device
0301011U0AAAAAA
|
Salmeterol | Salmeterol | Respiratory System | No data available |
|
Salmeterol 50microgram inhalation powder blisters
0301011U0AAABAB
|
Salmeterol | Salmeterol | Respiratory System | No data available |
|
Seffalair Spiromax 12.75microg / 100microg/dose dry pdr inh
0302000N0BQAABR
|
Seffalair Spiromax | Fluticasone propionate (Inhalation) | Respiratory System | No data available |
|
Seffalair Spiromax 12.75microg / 202microg/dose dry pdr inh
0302000N0BQABBS
|
Seffalair Spiromax | Fluticasone propionate (Inhalation) | Respiratory System | No data available |
|
Semprex 8mg capsules
0304010A0BBAAAA
|
Semprex | Acrivastine | Respiratory System | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.